• Coya Therapeutics entered sales agreement with Leerink Partners for an at-the-market equity program of up to USD 30 million of common stock.
• Shares may be sold from time to time through Leerink Partners, including sales on Nasdaq.
• Leerink Partners will receive 3% commission on gross proceeds from any shares sold.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Coya Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-218282), on May 12, 2026, and is solely responsible for the information contained therein.